Provided by Tiger Trade Technology Pte. Ltd.

Foghorn Therapeutics Inc.

4.64
+0.16003.57%
Post-market: 4.640.00000.00%16:10 EST
Volume:173.28K
Turnover:809.33K
Market Cap:262.30M
PE:-4.05
High:4.90
Open:4.51
Low:4.44
Close:4.48
52wk High:6.79
52wk Low:2.94
Shares:56.53M
Float Shares:26.76M
Volume Ratio:1.14
T/O Rate:0.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1460
EPS(LYR):-1.5778
ROE:-470.38%
ROA:-21.07%
PB:-2.93
PE(LYR):-2.94

Loading ...

Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Bicycle Therapeutics (BCYC) and Foghorn Therapeutics (FHTX)

TIPRANKS
·
Oct 31

Foghorn Therapeutics Inc - Selective Cbp Degrader Ind-Ready in 2026

THOMSON REUTERS
·
Oct 30

Foghorn Therapeutics Inc - Selective Arid1b Degrader Relevant in 5% of Solid Tumors

THOMSON REUTERS
·
Oct 30

Foghorn Therapeutics Announces Updates for Selective Arid1b, Selective Cbp and Selective Ep300 Degrader Programs

THOMSON REUTERS
·
Oct 30

Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs

GlobeNewswire
·
Oct 30

Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader Program Targeting Cancer at TPD Summit

Reuters
·
Oct 16

Foghorn Therapeutics Announces Significant Progress for Selective Arid1b Degrader at the 8TH Annual Tpd and Induced Proximity Summit

THOMSON REUTERS
·
Oct 16

Foghorn Therapeutics transferred with Buy rating at B. Riley

TIPRANKS
·
Sep 17

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

GlobeNewswire
·
Aug 27

Foghorn Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 06

Foghorn Therapeutics Q2 collaboration revenue rises, loss narrows

Reuters
·
Aug 05

Foghorn Therapeutics Inc - Selective Cbp Degrader on Track for Ind Studies in 2026

THOMSON REUTERS
·
Aug 05

Foghorn Therapeutics Inc - Has $198.7 Mln Cash, Runway Into 2028

THOMSON REUTERS
·
Aug 05

Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update

GlobeNewswire
·
Aug 05

Foghorn Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
Aug 04

Foghorn Therapeutics Signs Major Lease Agreement for New Watertown Headquarters

Reuters
·
Jul 02

Foghorn Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jun 18